Netherlands · Delayed Price · Currency is EUR Lakefront Biotherapeutics NV Earnings Call Transcripts
Fiscal Year 2026
-
The company has undergone a major transformation, focusing on T-cell engagers and securing gamgertamig as a lead asset with Gilead as a key partner. Registration studies in autoimmune diseases are set for next year, supported by strong financials and a robust pipeline. Regulatory and industry trends are favorable.
-
Q1 2026 saw a major transformation, including a new name, leadership, and a pivotal partnership with Gilead for Ouro Medicines' portfolio. Financials improved with a net profit of EUR 14.5 million and robust cash reserves, while guidance reflects significant investment in new programs and continued capital discipline.
-
Galapagos and Gilead entered a partnership to co-develop Gamgertamig for autoimmune diseases, sharing costs and leveraging each other's strengths. The deal unlocks $500 million for Galapagos to pursue further R&D or strategic transactions, while integrating Ouro’s team and pipeline. Registrational studies are planned for 2027.
Fiscal Year 2025
-
2025 saw a strategic pivot, with a strong cash position, major restructuring, and a focus on business development. Operating profit rebounded due to deferred income recognition, and the company expects to be cash flow neutral or positive by end-2026.
-
A major transformation is underway, with a strategic exit from cell therapy and a focus on redeploying €3 billion in cash into de-risked immunology and oncology assets. Key catalysts ahead include the cell therapy wind down, TIC2 phase 2 data, and new business development deals.
-
Announced wind down of the cell therapy business after failed sale, incurring major impairments and restructuring costs. Focus shifts to business development, leveraging a strong cash position and Gilead partnership to pursue de-risked opportunities in oncology and immunology.
-
Leadership transitions and SpinCo separation mark a transformative year, with strong Q1 revenues, robust cash position, and pivotal progress in cell therapy pipeline. GLPG5101 advances toward pivotal MCL trial, while decentralized manufacturing and global partnerships expand access.
-
A major strategic separation will create two focused, well-capitalized companies: one advancing cell therapies and decentralized manufacturing, and the other (SpinCo) building a pipeline of innovative medicines with Gilead. Key cell therapy programs show strong clinical progress, with pivotal studies and approvals targeted for 2026–2028.
-
A major restructuring will split the business into a cell therapy-focused entity and SpinCo, which will pursue acquisitions in oncology, immunology, and virology with €2.45 billion in capital. The cell therapy platform features rapid, decentralized manufacturing and strong clinical data, while both entities are positioned for long-term value creation.
-
Galapagos will split into two entities: one focused on cell therapy with a decentralized manufacturing platform and a €500 million cash runway, and SpinCo, capitalized with €2.45 billion, targeting acquisitions in oncology, immunology, and virology. The restructuring includes significant workforce reductions and aims to accelerate R&D and value creation for shareholders.
Fiscal Year 2024
-
2024 saw major progress in cell therapy, highlighted by strong GLPG5101 data, FDA IND clearance, and a strategic split into two entities. Financials showed €276M revenue, €74M net profit, and €3.3B cash, with a focus on pivotal trials and next-gen therapies ahead.
-
Q3 2024 saw stable revenue, increased R&D investment, and a strong EUR 3.3B cash position. Key milestones included FDA IND clearance for GLPG5101, resumption of GLPG5301, and expansion of the decentralized CAR-T network. Multiple pipeline and business development advances were highlighted.
-
Focused on oncology and immunology, achieved strong clinical progress in CAR-T programs, and expanded the cell therapy pipeline through key partnerships. Maintained a robust €3.4B cash position, with increased R&D investment and updated cash burn guidance reflecting recent business development.